Eximias Pharmaceutical Report issue

For profit Phase 3
Founded: Berwyn PA United States (1997)
Status: Acquired by YM Biosciences (2006) → now Gilead Sciences (2013)

Organization Overview

First Clinical Trial
2000
NCT00012324
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2000

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (2)

doxorubicin (Doxil) (1 trial)

nolatrexed (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Liver Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 2